Not investment advice. FilingSight is an automated analytical research tool, not a registered investment advisor. Ratings and scores are quantitative analytical classifications, not buy or sell recommendations. Nothing here is personalized to your circumstances. Investing involves risk of loss — consult a licensed professional. See full disclosures.
Abbott Laboratories
ABTHealthcareGenerated Aug 19, 2026, 10:33 PM UTC
ABT (Abbott Laboratories) analytical snapshot. Revenue grew +5.7% YoY to $44.33B. 5-year revenue CAGR +0.6%; 10y CAGR +8.7%. Net margin at 14.72% (contracting ▼). Market cap $199.32B at $114.43 per share. Trailing P/E 30.76, P/S 4.50, P/B 3.83. EV/Operating income ≈ 25.51 (EV $205.44B). Risk: Moderate. Macro: Risk-on · Supportive. Composite analytical score 7 (data confidence 83%). Descriptive analytics from public filings — not investment advice.
Free SEC analysis
— computed from SEC filings, free to readFilings & Ownership
Latest annual report (10-K) filed Feb 20, 2026. Latest quarterly report (10-Q) filed Jul 28, 2026. 14 recent 8-K material-event filings in the index.
- Latest annual report (10-K) filed Feb 20, 2026.
- Latest quarterly report (10-Q) filed Jul 28, 2026.
- 14 recent 8-K material-event filings in the index.
- Recent insider Form 4s: 0 buy vs 0 sell transactions.
- ~10,000+ recent 13F-HR filings reference Abbott Laboratories; broad institutional reporting.
- Recent filers include THURSTON, SPRINGER, MILLER, HERD & TITAK, INC., LORING WOLCOTT & COOLIDGE FIDUCIARY ADVISORS /MA, LORING WOLCOTT & COOLIDGE FIDUCIARY ADVISORS /MA.
- 8 recent 13D activist/beneficial-ownership filings — potential catalyst.
- 12 recent 13G passive institutional ownership notices.
| Filer | Form | Filed |
|---|---|---|
| THURSTON, SPRINGER, MILLER, HERD & TITAK, INC. | 13F-HR | May 14, 2024 |
| LORING WOLCOTT & COOLIDGE FIDUCIARY ADVISORS /MA | 13F-HR | Aug 9, 2002 |
| LORING WOLCOTT & COOLIDGE FIDUCIARY ADVISORS /MA | 13F-HR | May 15, 2003 |
| LORING WOLCOTT & COOLIDGE FIDUCIARY ADVISORS /MA | 13F-HR | May 8, 2001 |
| LORING WOLCOTT & COOLIDGE FIDUCIARY ADVISORS /MA | 13F-HR | Nov 2, 2001 |
| Date | Form | Description |
|---|---|---|
| Jul 16, 2026 | 8-K | 8-K |
| Apr 27, 2026 | 8-K | FORM 8-K |
| Apr 17, 2026 | 8-K | FORM 8-K |
| Apr 16, 2026 | 8-K | 8-K |
| Mar 23, 2026 | 8-K | FORM 8-K |
| Mar 9, 2026 | 8-K | FORM 8-K |
| Feb 26, 2026 | 8-K | FORM 8-K |
| Feb 20, 2026 | 8-K | FORM 8-K |
SEC Filing Deep-Analysis
1 risk signal(s), 1 positive signal(s), 1 watch item(s) detected from XBRL filing diff analysis. 1 positive signal(s) versus 1 risk signal(s). The filing exhibits more constructive indicators than concerns, though individual risk factors should still be monitored.
- NEW: Restatement of financial statements in latest filing: The term "restatement of" "previously issued" appears in recent 10-K/10-Q filings but was NOT present in the prior 24-month period. This is a new risk disclosure that warrants attention. Found in 1 filing(s).
- Operating cash flow exceeds net income: OCF is 1.47x net income, indicating high earnings quality — cash conversion is strong and accruals are not inflating reported profits.
- Goodwill is 32% of total assets: Goodwill of $35.22B represents a large share of the balance sheet. If acquired businesses underperform, a non-cash impairment charge could materially impact earnings. Monitor segment performance and acquisition integration metrics.
- Endogenous analysis: 1 positive signal(s) versus 1 risk signal(s). The filing exhibits more constructive indicators than concerns, though individual risk factors should still be monitored.
- 2 new XBRL disclosure(s) in latest filing — expanding reporting scope.
- 20 disclosure(s) dropped from prior year — reduced reporting granularity.
- 1 new risk-language term(s) detected in filing text: Restatement of financial statements.
| Metric | Prior year | Latest year | Change | % Change |
|---|---|---|---|---|
| Revenue | $41.95B | $44.33B | $2.38B | +5.7% |
| Gross profit | $4.23B | $4.40B | $163.0M | +3.8% |
| Operating income | $6.83B | $8.05B | $1.23B | +18.0% |
| Net income | $13.40B | $6.52B | $-6.88B | -51.3% |
| Operating cash flow | $8.56B | $9.57B | $1.01B | +11.8% |
| Capex | $2.21B | $2.17B | $-36.0M | -1.6% |
| Total assets | $81.41B | $86.71B | $5.30B | +6.5% |
| Long-term debt | $14.13B | $12.93B | $-1.20B | -8.5% |
| Cash & equivalents | $7.62B | $8.52B | $906.0M | +11.9% |
| Stockholders equity | $47.66B | $52.13B | $4.47B | +9.4% |
| Inventory | $6.19B | $6.49B | $294.0M | +4.7% |
| Accounts receivable | $6.92B | $7.93B | $1.00B | +14.5% |
| R&D expense | $2.84B | $2.94B | $98.0M | +3.4% |
| SG&A expense | $11.70B | $12.33B | $635.0M | +5.4% |
| Interest expense | $558.0M | $637.0M | $79.0M | +14.2% |
| Type | Concepts |
|---|---|
| Added | BusinessCombinationProFormaInformationEarningsOrLossOfAcquireeSinceAcquisitionDateActual, ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsShareBasedLiabilitiesPaid |
| Removed | AllocatedShareBasedCompensationExpense, BuildingsAndImprovementsGross, ConstructionInProgressGross, CurrentFederalStateAndLocalTaxExpenseBenefit, CurrentFederalTaxExpenseBenefit, CurrentForeignTaxExpenseBenefit, CurrentIncomeTaxExpenseBenefit, CurrentStateAndLocalTaxExpenseBenefit, DeferredFederalIncomeTaxExpenseBenefit, DeferredFederalStateAndLocalTaxExpenseBenefit |
| Term | Severity | Recent | Prior | Status |
|---|---|---|---|---|
| Restatement of financial statements | high | 1 | 0 | NEW |
| Impairment charge | medium | 5 | 3 | Ongoing |
| Restructuring | medium | 5 | 10 | Ongoing |
| Off-balance sheet arrangements | medium | 5 | 2 | Ongoing |
| Related party transactions | low | 5 | 2 | Ongoing |
Fundamentals
Revenue grew +5.7% YoY to $44.33B. 5-year revenue CAGR +0.6%; 10y CAGR +8.7%. Net margin at 14.72% (contracting ▼).
- Revenue grew +5.7% YoY to $44.33B.
- 5-year revenue CAGR +0.6%; 10y CAGR +8.7%.
- Net margin at 14.72% (contracting ▼).
- Return on equity 12.51%, ROA 7.52%, ROIC 12.38%.
- Gross margin 0.00%, operating margin 18.17%.
- Free cash flow margin 16.68% ($7.39B).
- Net income down ▼ +51.3% YoY.
- Debt/equity 0.25, current ratio 1.39, net debt $6.13B.
- Asset turnover 0.40 — capital efficiency.
| FY | Revenue | Rev YoY | Gross% | Op% | Net% | FCF | ROE% |
|---|---|---|---|---|---|---|---|
| 2024 | $41.95B | +4.6% | 0.00 | 16.27 | 31.95 | $6.35B | 28.12 |
| 2025 | $44.33B | +5.7% | 0.00 | 18.17 | 14.72 | $7.39B | 12.51 |
| Quarter end | Revenue | YoY | QoQ | Net margin |
|---|---|---|---|---|
| Jun 30, 2024 | $10.38B | +4.0% | — | 12.55% |
| Sep 30, 2024 | $10.63B | +4.9% | +2.5% | 15.48% |
| Mar 31, 2025 | $10.36B | +4.0% | -2.6% | 12.79% |
| Jun 30, 2025 | $11.14B | +7.4% | +7.6% | 15.97% |
| Sep 30, 2025 | $11.37B | +6.9% | +2.0% | 14.46% |
| Mar 31, 2026 | $11.16B | +7.8% | -1.8% | 9.65% |
Pro analysis — preview
— score, signals & key metrics shown; full reasoning lockedValuation
Market cap $199.32B at $114.43 per share. Trailing P/E 30.76, P/S 4.50, P/B 3.83. EV/Operating income ≈ 25.51 (EV $205.44B).
- Market cap $199.32B at $114.43 per share.
Price & Technicals
Price $114.43 — uptrend (above 200-DMA); 1-month momentum positive. RSI(14) 80.97 (overbought).
- Price $114.43 — uptrend (above 200-DMA); 1-month momentum positive.
Macro & Rates
Risk-on · Supportive. Real GDP growth 1.50% (quarterly, as of Apr 1, 2026). CPI inflation +3.3% YoY. Fed funds rate 3.63%, 10Y Treasury 4.71%.
- Market regime: Risk-on · Supportive.
Risk Scorecard
Composite risk Moderate. Leverage debt/equity 0.25 (low). Liquidity current ratio 1.39 (adequate).
- Composite risk: Moderate.
See the full picture behind every stock
Unlock the complete 10-year fundamentals, DCF & Graham intrinsic value, 13F/13D ownership flow, risk scorecard, multi-analyst bull/bear debate — plus watchlist alerts and your research workspace. Start with a 14-day Pro trial.
3 sections free · 4 Pro previews · composite 7
Macro exposure
Defensive · Low sensitivityMacro regime: Risk-on · Supportive. Abbott Laboratories is a defensive name (low macro sensitivity) — a supportive backdrop, though defensives lag risk-on tapes.
Analytical read
deterministic previewRevenue grew **+5.7%** YoY to $44.33B..
Peer comparison
Defensive groupHow ABT stacks up against tracked peers with similar macro sensitivity — by analytical score and macro exposure.
| Company | Score | Macro |
|---|---|---|
| DexCom Inc. DXCM | 21 | Neutral |
| Bristol-Myers Squibb BMY | 19 | Neutral |
| Eli Lilly & Co. LLY | 17 | Neutral |
| HCA Healthcare HCA | 9 | Neutral |
| Gilead Sciences GILD | 8 | Neutral |
| Johnson & Johnson JNJ | 8 | Neutral |
| Abbott Laboratories ABT● you | 7 | Neutral |
| Biogen Inc. BIIB | 7 | Neutral |
| Intuitive Surgical Inc. ISRG | 7 | Neutral |
| Coca-Cola Co. KO | 6 | Neutral |
| Thermo Fisher Scientific TMO | 3 | Neutral |
| Regeneron Pharmaceuticals REGN | 3 | Neutral |
| Danaher Corp. DHR | 1 | Neutral |
| Merck & Co. MRK | 0 | Neutral |
| Zoetis Inc. ZTS | 0 | Neutral |
| Illumina Inc. ILMN | 0 | Neutral |
| Colgate-Palmolive CL | -2 | Neutral |
| Vertex Pharmaceuticals VRTX | -2 | Neutral |
| AbbVie Inc. ABBV | -5 | Neutral |
| Procter & Gamble PG | -7 | Neutral |
| CVS Health Corp. CVS | -8 | Neutral |
| Mondelez International MDLZ | -10 | Neutral |
| Amgen Inc. AMGN | -10 | Neutral |
| Cigna Group CI | -11 | Neutral |
| Kroger Co. KR | -12 | Neutral |
| Costco Wholesale COST | -14 | Neutral |
| Walmart Inc. WMT | -14 | Neutral |
| Pfizer Inc. PFE | -15 | Neutral |
| PepsiCo Inc. PEP | -16 | Neutral |
| Sysco Corp. SYY | -16 | Neutral |
| Hershey Co. HSY | -17 | Neutral |
| Kimberly-Clark Corp. KMB | -18 | Neutral |
| Moderna Inc. MRNA | -21 | Neutral |
| UnitedHealth Group UNH | -25 | Neutral |